PLoS ONE (Jan 2018)

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.

  • Anne Walter,
  • Apirat Chaikuad,
  • Renate Helmer,
  • Nadège Loaëc,
  • Lutz Preu,
  • Ingo Ott,
  • Stefan Knapp,
  • Laurent Meijer,
  • Conrad Kunick

DOI
https://doi.org/10.1371/journal.pone.0196761
Journal volume & issue
Vol. 13, no. 5
p. e0196761

Abstract

Read online

Cdc2-like kinases (CLKs) represent a family of serine-threonine kinases involved in the regulation of splicing by phosphorylation of SR-proteins and other splicing factors. Although compounds acting against CLKs have been described, only a few show selectivity against dual-specificity tyrosine phosphorylation regulated-kinases (DYRKs). We here report a novel CLK inhibitor family based on a 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one core scaffold. Within the series, 3-(3-chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (KuWal151) was identified as inhibitor of CLK1, CLK2 and CLK4 with a high selectivity margin towards DYRK kinases. The compound displayed a potent antiproliferative activity in an array of cultured cancer cell lines. The X-ray structure analyses of three members of the new compound class co-crystallized with CLK proteins corroborated a molecular binding mode predicted by docking studies.